Summary
The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), is soliciting proposals from small business concerns to demonstrate technical feasibility and proof-of-concept for transformative technologies in two specific topic areas focused on Pediatric and/or Rare Cancers (Topic 1: therapeutic or preventative technologies; Topic 2: devices, diagnostic technologies, or digital health tools). This is a total small business set-aside federal contract opportunity posted as a presolicitation (Notice ID 75N91026R00109, NAICS 54171) on July 2, 2026, with presolicitation responses due by 5:00 pm EDT on July 17, 2026; the full solicitation is anticipated to be issued on or around July 17, 2026. Phase I Concept Awards of up to $300,000 support early-stage, high-risk, high-reward innovations that ultimately feed into the federal SBIR program pipeline.